摘要
阿尔茨海默病(AD)是目前重大慢性疾病领域中尚无法治愈的疾病。主观认知下降(SCD)是AD的临床危险因素,对SCD人群进行规范化筛查以及干预是AD早期防治的重要关口。根据Lancet Neurology在线发表的《主观认知下降特征》临床标准,我们全面地整理了SCD的概念、最新标准和AD临床前期SCD研究结果,为开展临床诊断与研究SCD提供了具体的指导和建议。
Alzheimer′s disease(AD)is an incurable disease in the field of major chronic diseases.Subjective cognitive decline(SCD)is a clinical risk factor for AD.The standardized screening and intervention in individuals with SCD are of great importance in early prevention and treatment of AD.According to the clinical criteria proposed by The characterisation of subjective cognitive decline,which was published online in Lancet Neurology,the article summarized the definition of SCD,the latest perspective of clinical standards in SCD,and the results of AD preclinical SCD research.The purpose of this work was to provide concrete guidance and recommendations for making clinical decisions in diagnosis and scientific research on SCD.
作者
孙宇
王晓妮
陈观群
盛灿
李轩宇
杨勤
李陶然
杜文莹
王小琪
林立
刘奕
冯逢
胡笑晨
韩璎
Sun Yu;Wang Xiaoni;Chen Guanqun;Sheng Can;Li Xuanyu;Yang Qin;Li Taoran;Du Wenying;Wang Xiaoqi;Lin Li;Liu Yi;Feng Feng;Hu Xiaochen;Han Ying(Department of Neurology,Xuanwu Hospital of Capital Medical University,Beijing 100053,China;Department of Radiology,Peking Union Medical College Hospital,Beijing 100730,China;Department of Psychiatry and Psychotherapy,University of Cologne,Medical Faculty,Cologne 50937,Germany)
出处
《中华神经科杂志》
CAS
CSCD
北大核心
2020年第5期396-400,共5页
Chinese Journal of Neurology
基金
国家自然科学基金重点项目(61633018)。
关键词
认知障碍
阿尔茨海默病
生物学标记
临床前期
Cognition disorders
Alzheimer disease
Biological markers
Preclinical phase
